Work

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Year: 2014

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(14)60538-9

Authors: Michael Manns, Patrick Marcellin, Fred Poordad, Evaldo Stanislau Affonso de Araujo, Maria Buti, Yves Horsmans, Ewa Janczewska, Federico Villamil, Jane Scott, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Guy De La Rosa, Ronald Kalmeijer, Rekha Sinha, Maria Beumont-Mauviel

Institutions: Medizinische Hochschule Hannover, Inserm, Hôpital Beaujon, Université Paris Diderot, The University of Texas at San Antonio Health Science Center, Texas Liver Institute, Universidade de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Vall d'Hebron Hospital Universitari, UCLouvain, Janssen (United Kingdom), Janssen (Belgium), Janssen (United States)

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2127189337

FWCI: 48.61

Cites: 43

Cited by: 376

Related to: 10